OXiGENE, Inc. is a biopharmaceutical company primarily focused on the development of vascular disrupting agents (VDAs), for the treatment of cancer. The Company has two clinical-stage product candidates. The Company is testing its lead compound fosbretabulin tromethamine (fosbretabulin) in two indications, recurrent ovarian cancer and gastrointestinal neuroendocrine tumors (GI-NETs). The Company is testing its second compound, OXi4503, in patients with relapsed or refractory acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). The Company’s product fosbretabulin is a small molecule, reversible inhibitor of tubulin polymerization. Similar to fosbretabulin, OXi4503 is a small molecule reversible inhibitor of tubulin polymerization. Additionally, orthoquinone metabolite, which is formed via oxidation, has anti-proliferative effect on leukemic cells.
